Monitor the stock price closely — if LTRN fails to sustain a market cap above $35 million for 10 consecutive days by March 24, 2027, delisting is likely. The recent dilutive offering at $1.09 suggests the company is burning cash rapidly; watch for any reverse split announcement or further capital raises as potential compliance strategies.
Price Chart
Executive Summary
Lantern Pharma received a Nasdaq delisting notice on September 25, 2026, for failing to meet the $35 million minimum market value of listed securities (MVLS) requirement under Listing Rule 5550(b)(2), and also noted non-compliance with Rules 5550(b)(1) and 5550(b)(3). The company has 180 days, until March 24, 2027, to regain compliance by closing at $35 million or more for 10 consecutive business days. This delisting risk follows a dilutive $4.0 million offering filed just one day prior, compounding the financial distress.
Key Facts
- Nasdaq notified Lantern Pharma on September 25, 2026, of non-compliance with Listing Rule 5550(b)(2) (MVLS < $35 million for 30 consecutive business days).
- Nasdaq also noted the company does not meet requirements under Listing Rules 5550(b)(1) and 5550(b)(3).
- The company has 180 calendar days, until March 24, 2027, to regain compliance.
- To regain compliance, the MVLS must close at $35 million or more for a minimum of 10 consecutive business days.
- If compliance is not regained, Nasdaq would provide notice that the securities are subject to delisting from the Nasdaq Capital Market.
- A dilutive offering of 1,469,725 shares of common stock and 2,200,000 pre-funded warrants was filed on September 30, 2026, raising approximately $4.0 million at $1.09 per share.
Financial Impact
The company's market value of listed securities fell below the $35 million minimum threshold. The recent $4.0 million offering at $1.09 per share further dilutes existing shareholders while providing limited cash runway.
Risk Factors
- Failure to regain compliance by March 24, 2027, would result in delisting from Nasdaq, severely reducing liquidity and institutional ownership.
- The dilutive offering just prior to the delisting notice signals acute cash needs and may further depress the stock price, making compliance harder.
- The company also failed to meet alternative listing standards (5550(b)(1) and 5550(b)(3)), limiting compliance options.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-045344 |
| Document: 0001493152-26-045344-index-headers.html | 0001493152-26-045344 |
| Document: 0001493152-26-045344-index.html | 0001493152-26-045344 |
| Document: 0001493152-26-045344.txt | 0001493152-26-045344 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $0.6564 | awaiting T+60 | — | $0.6106 (+6.98%) |
Oct 13, 2026 13d ago | SC 13G/A | $0.7107 | awaiting T+60 | — | $0.6106 (−14.08%) |
Oct 1, 2026 25d ago | 8-K | $0.8601 | awaiting T+60 | — | $0.6106 (+29.01%) |
Sep 30, 2026 26d ago | 8-K | $1.00 | awaiting T+60 | — | $0.6106 (+38.94%) |
Sep 30, 2026 27d ago | 424B5 | $1.01 | awaiting T+60 | — | $0.6106 (+39.54%) |
Sep 23, 2026 4w ago | 8-K | $1.21 | awaiting T+60 | — | $0.6106 (−49.54%) |
Sep 23, 2026 4w ago | 8-K | $1.39 | awaiting T+60 | — | $0.6106 (−56.07%) |
Aug 14, 2026 10w ago | 8-K | $2.65 | awaiting T+60 | — | $0.6106 (−76.96%) |
Jun 22, 2026 18w ago | EFFECT | $3.88 $1.70 | ▲ +56.19% | ▲ +57.93% | $0.6106 (+84.26%) |
May 15, 2026 23w ago | 8-K | $3.00 $2.66 | ▼ −11.33% | ▼ −16.18% | $0.6106 (−79.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers